When last I wrote on Integra LifeSciences (IART), I was worried about what looked liked slowing momentum in the company's orthopedics business, excessively optimistic guidance, and some issues with the FDA. Both of these concerns fell to earth with a “thud” Thursday night as the company announced a very poor performance for the fourth quarter and a formal warning letter from the FDA concerning its Plainsboro facility.
Bad To Worse In Q4
Integra LifeSciences is hardly alone in seeing weaker trends lately in markets like orthopedics and neurology. Much larger companies like Johnson & Johnson (JNJ), Medtronic (MDT), and Stryker (SYK) have been reporting the same sort of malaise as hospitals and distributors pare down inventory in the face of low patient volumes and a less certain reimbursement environment.
Please follow this link for the full piece:
Integra LifeSciences Sputters At Year End, But Is Still Undervalued
No comments:
Post a Comment